The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children
Official Title: A Multicenter, Prospective, Open and Single Arm Clinical Study of Nimotuzumab Combined With Concurrent Radiochemotherapy in the Treatment of Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Children
Study ID: NCT04532229
Brief Summary: This is a prospective, open-label, single arm, multicenter clinical study. The purpose of the study is to evaluate the clinical efficacy and safety of combination Nimotuzumab with concurrent radiochemotherapy in children with newly diagnosed diffuse intrinsic pontine glioma(DIPG).
Detailed Description: This clinical study is designed as a prospective, open-label, single arm, multicenter study to evaluate the clinical efficacy and safety of combination Nimotuzumab with concurrent radiochemotherapy in children with newly diagnosed diffuse intrinsic pontine glioma(DIPG). The main endpoint is objective response rate, 1-year overall survival rate is also observed.
Minimum Age: 3 Years
Eligible Ages: CHILD
Sex: ALL
Healthy Volunteers: No
The Third People's Hospital of Zhengzhou, Zhengzhou, Henan, China
Xiangya Hospital of Centre-south University, Changsha, Hunan, China
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Beijing Tiantan Hospital, Capital Medical University, Beijing, , China
Peking Union Medical College Hospital, Beijing, , China
Xuanwu Hospital Capital Medical University, Beijing, , China
Shandong Cancer Hospital, Jinan, , China
Xinhua Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine, Shanghai, , China
Name: Xiaojun Yuan
Affiliation: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Role: STUDY_CHAIR
Name: Xiaoguang Qiu
Affiliation: Beijing Tiantan Hospital
Role: STUDY_CHAIR